Fundraising FoxWRF Capital — 2024 Investments
3 investments dated 2024 · listed companies and verified rows first · show all
Outpace Bio develops engineered protein technologies and cell therapies to treat solid tumors, focusing on protein design and T cell engineering to improve cancer treatment efficacy and safety.
BiotechDeep TechMedical DevicesSeattle, US
Marc Lajoie(Founder)inScott Boyken(Founder)inStanley Riddell(Co-Founder and Scientific Advisor)Aaron Foster(Executive Officer)inCharity Scripture(Executive Officer)inEric Soller(Executive Officer)in
Co-investorsArtis VenturesRA CapitalAbstract VenturesATEL VenturesAtinum Investment Co. Ltd.Civilization Ventures Management, Llc+9 more
Proniras Corporation is a clinical-stage biotechnology company developing novel small-molecule therapeutics for substance use disorders and specialty central nervous system (CNS) conditions, including treatments for opioid withdrawal and seizure disorders.
BiotechHealthtechSeattle, US
CHRISTOPHER TOOMBS(Executive Officer)inLINDSAY RAYLE(Executive Officer, Promoter)M. Johnston Erwin(Director)David Schubert(Executive Officer, Promoter)
BoardSTEVEN GILLIS(Director)inThong Le(Executive Officer, Director, Promoter)
Co-investorsACCELERATOR LIFE SCIENCE PARTNERSAlexandriaARCH Venture Partners
Talus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts.
AI & Machine LearningBiotechDeep TechHealthtechSeattle, US
Alex Federation(Founder)inLindsay Pino(Founder)inAlex Federation, Ph.D.(Chief Executive Officer & Co-Founder)Lindsay Pino, Ph.D.(Chief Technology Officer & Co-Founder)
BoardOmri Amirav-Drory(Director)inJ. Seth Strattan(Director)in
Co-investorsFarvatn VentureFifty YearsFundersClubGaingelsJude GomilaNFX+12 more
__Twitter.png)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.